Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tebipenem Pivoxil Hydrobromide with Antacid and Omeprazole in Healthy Adults
NCT04368585Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of tebipenem in complicated urinary tract infection (cUTI) (3 arms), sponsored by Spero Therapeutics. Primary endpoints: Area under the concentration-time curve from time 0 to the last observed non-zero concentration at Day 6, Area under the curve extrapolated to infinity at Day 6 and 6 more. Started Jul 2020; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT04368585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368585.